Wen-Jun Bian
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Wen-Jun Bian has a total of 31 co-authors. Here are the top co-authors by number of shared publications:
Jie Wang
Department of Neurology, Institute of Neuroscience, Key Laboratory of Neurogenetics and Channelopathies of Guangdong Province and the Ministry of Education of China, The Second Affiliated Hospital, Guangzhou Medical University, Guangzhou, Guangdong, China
2 shared publications- Wei-Ping Liao
Department of Neurology, Institute of Neuroscience, Key Laboratory of Neurogenetics and Channelopathies of Guangdong Province and the Ministry of Education of China, The Second Affiliated Hospital Guangzhou Medical University Guangzhou China
2 shared publications Bin Li
Key Laboratory of Neurogenetics and Channelopathies of Guangdong Province and the Ministry of Education of China, The Second Affiliated Hospital, Guangzhou Medical University, Guangzhou, China
1 shared publication- Bin Li
Department of Neurology, Key Laboratory of Neurogenetics and Channelopathies of Guangdong Province Institute of Neuroscience, Second Affiliated Hospital of Guangzhou Medical University, The Ministry of Education of China Guangzhou China
1 shared publication Bin Tang
Department of Neurology, Institute of Neuroscience, Key Laboratory of Neurogenetics and Channelopathies of Guangdong Province and the Ministry of Education of China, The Second Affiliated Hospital, Guangzhou Medical University, Guangzhou, Guangdong, China
1 shared publicationCui-Xia Fan
Key Laboratory of Neurogenetics and Channelopathies of Guangdong Province and the Ministry of Education of China, The Second Affiliated Hospital, Guangzhou Medical University, Guangzhou, China
1 shared publication
Latest Publications
- Open Access
- 4 July 2024
- Published by BMJ in Journal of Medical Genetics
- Vol. 61 (9) , 895-903
IFIH1 variants are associated with generalised epilepsy preceded by febrile seizures
Background: IFIH1 variants have been reported to be associated with immune-related disorders with/without seizures. It is unknown whether IFIH1 variants are associated with common epilepsy without acquired causes and the mechanism underlying phenotypic variation remains elusive. Methods: Trio-based whole-exome sequencing was performed on patients with febrile seizures or epilepsy with antecedent febrile seizures. Previously reported variants were systematically reviewed to investigate genotype-phenotype associations. Results: Two de novo heterozygous and three biallelic missense variants were identified in five patients with generalised epilepsy with antecedent febrile seizures. The variants were predicted to be damaging by in silico tools and were associated with hydrogen bonding changes to neighbouring amino acids or decreased protein stability. Patients exhibited an early onset age and became seizure-free with favourable outcome. Further analysis revealed that de novo missense variants located in the Hel region resulted in seizures with multiple neurological abnormalities, while those in the pincer domain or C-terminal domain led to seizures with normal neurodevelopment, suggesting a sub-molecular effect. Biallelic missense variants, which were inherited from unaffected parents and presented low allele frequencies in general populations, were associated with seizures without neurological abnormalities. Truncation variants were related to refractory epilepsy and severe developmental delay, suggesting a genotype-phenotype correlation. IFIH1 is predominantly expressed in the neonatal stage and decreases dramatically in the adulthood, which is consistent with the early onset age and favourable outcome of the patients. Conclusions: IFIH1 variants are potentially associated with generalised epilepsy with antecedent febrile seizures. The sub-molecular implication and genotype-phenotype association help explain phenotype variations of IFIH1 variants.
- 4 July 2024
- Published by BMJ in Journal of Medical Genetics
- Vol. 61 (9) , 895-903
Open AccessIFIH1 variants are associated with generalised epilepsy preceded by febrile seizures
Background: IFIH1 variants have been reported to be associated with immune-related disorders with/without seizures. It is unknown whether IFIH1 variants are associated with common epilepsy without acquired causes and the mechanism underlying phenotypic variation remains elusive. Methods: Trio-based whole-exome sequencing was performed on patients with febrile seizures or epilepsy with antecedent febrile seizures. Previously reported variants were systematically reviewed to investigate genotype-phenotype associations. Results: Two de novo heterozygous and three biallelic missense variants were identified in five patients with generalised epilepsy with antecedent febrile seizures. The variants were predicted to be damaging by in silico tools and were associated with hydrogen bonding changes to neighbouring amino acids or decreased protein stability. Patients exhibited an early onset age and became seizure-free with favourable outcome. Further analysis revealed that de novo missense variants located in the Hel region resulted in seizures with multiple neurological abnormalities, while those in the pincer domain or C-terminal domain led to seizures with normal neurodevelopment, suggesting a sub-molecular effect. Biallelic missense variants, which were inherited from unaffected parents and presented low allele frequencies in general populations, were associated with seizures without neurological abnormalities. Truncation variants were related to refractory epilepsy and severe developmental delay, suggesting a genotype-phenotype correlation. IFIH1 is predominantly expressed in the neonatal stage and decreases dramatically in the adulthood, which is consistent with the early onset age and favourable outcome of the patients. Conclusions: IFIH1 variants are potentially associated with generalised epilepsy with antecedent febrile seizures. The sub-molecular implication and genotype-phenotype association help explain phenotype variations of IFIH1 variants.
- Open Access
- 18 September 2023
- Published by Springer Nature in Research Square
Gene-disease association: pathogenic potential/pathogenic feature assessment
Determining gene-disease associationsis an essential task but a major challenge of genetic studies. It is also the precondition for evaluating the pathogenicity of variants. Considering what determines the gene-disease association and which clinical-genetic features reflect the gene-disease association, we proposed a pathogenic potential and pathogenic feature assessment (PPA) system to evaluate the gene-disease association. In addition to case/variant number, PPA evaluates the clinical-genetics evidence from phenotypic specificity, inheritance pattern, genotype-phenotype correlation, and submolecular implication of variants, which represent the pathogenic feature of the gene. PPA refers to experimental evidence directly related to gene-disease associations, including gene expression and knockout, and the functional consequencesof variants. We collected data on all potentially functioning genes (19,711) and assessed those with available clinical data, and 3,623 genes were evaluated as “pathogenic”/“possibly pathogenic”. The pathogenic features of genes were summarized, providing critical information for evaluating the pathogenicity of variants. PPA considers the genetic dependent feature that differs in each gene and determines the pathogenicity of genes and evaluates whether (pathogenic potential) and how (pathogenic feature) a gene is associated with a disease and avoidsbias associated with special genotype or inheritance, potentially being a framework in future studies in defining the gene-disease association.
- 18 September 2023
- Published by Springer Nature in Research Square
Open AccessGene-disease association: pathogenic potential/pathogenic feature assessment
Determining gene-disease associationsis an essential task but a major challenge of genetic studies. It is also the precondition for evaluating the pathogenicity of variants. Considering what determines the gene-disease association and which clinical-genetic features reflect the gene-disease association, we proposed a pathogenic potential and pathogenic feature assessment (PPA) system to evaluate the gene-disease association. In addition to case/variant number, PPA evaluates the clinical-genetics evidence from phenotypic specificity, inheritance pattern, genotype-phenotype correlation, and submolecular implication of variants, which represent the pathogenic feature of the gene. PPA refers to experimental evidence directly related to gene-disease associations, including gene expression and knockout, and the functional consequencesof variants. We collected data on all potentially functioning genes (19,711) and assessed those with available clinical data, and 3,623 genes were evaluated as “pathogenic”/“possibly pathogenic”. The pathogenic features of genes were summarized, providing critical information for evaluating the pathogenicity of variants. PPA considers the genetic dependent feature that differs in each gene and determines the pathogenicity of genes and evaluates whether (pathogenic potential) and how (pathogenic feature) a gene is associated with a disease and avoidsbias associated with special genotype or inheritance, potentially being a framework in future studies in defining the gene-disease association.